Table of Contents
ISRN Hematology
Volume 2013, Article ID 673781, 5 pages
http://dx.doi.org/10.1155/2013/673781
Research Article

Portal Hypertension and Myeloproliferative Neoplasms: A Relationship Revealed

1Liv Ulus Hospital, Department of Gastroenterohepatology, 34347 Istanbul, Turkey
2Istanbul Education and Research Hospital, Department of Internal Diseases, 34098 Istanbul, Turkey
3Bezmialem University Medical Faculty, Department of Haematology, 34093 Istanbul, Turkey
4Istanbul Education and Research Hospital, Department of Haematology, 34098 Istanbul, Turkey
5Istanbul Education and Research Hospital, Department of Radiology, 34098 Istanbul, Turkey
6Istanbul Education and Research Hospital, Department of Gastroenterohepatology, 34098 Istanbul, Turkey

Received 16 July 2013; Accepted 16 August 2013

Academic Editors: E. Abruzzese and F. Passamonti

Copyright © 2013 Ahmet Burak Toros et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Fauci, E. Braunwald, K. J. Isselbacher et al., Eds., Harrison's Principles of Internal Medicine, McGraw-Hill, New York, NY, USA, 15th edition, 2001.
  2. R. Hoffmann, E. J. Benz Jr, S. J. Shattil et al., Eds., Hematology Basic Principles and Practice, Churchill Livistone, New York, NY, USA, 3rd edition, 2000.
  3. R. G. Lee, J. Foerster, J. Lukens, F. Paraskevas, J. P. Greer, and G. M. Rodger, Eds., Wintrobe's Clinical Hematology, Williams & Wilkins, Baltimore, Md, USA, 10th edition, 1999.
  4. Y. Pikman, B. H. Lee, T. Mercher et al., “MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia,” PLoS Medicine, vol. 3, no. 7, article e270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. A. D. Pardanani, R. L. Levine, T. Lasho et al., “MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients,” Blood, vol. 108, no. 10, pp. 3472–3476, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Tefferi, “JAK and MPL mutations in myeloid malignancies,” Leukemia and Lymphoma, vol. 49, no. 3, pp. 388–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Oishi, S. N. Swisher, J. M. Stormont, and S. I. Schwartz, “Portal hypertension in myeloid metaplasia. Report of a case without,” Archives of Surgery, vol. 81, pp. 80–86, 1960. View at Google Scholar · View at Scopus
  8. D. L. Rosenbaum, G. W. Murphy, and S. N. Swisher, “Hemodynamic studies of the portal circulation in myeloid metaplasia,” The American Journal of Medicine, vol. 41, no. 3, pp. 360–368, 1966. View at Google Scholar · View at Scopus
  9. P. Jacobs, S. Maze, F. Tayob, and E. Harries-Jones, “Myelofibrosis, splenomegaly, and portal hypertension,” Acta Haematologica, vol. 74, no. 1, pp. 45–48, 1985. View at Google Scholar · View at Scopus
  10. P. Schiedermaier, “Splancnic hemodynamics: cirrhotic versus non-cirrhotic portal hypertension,” Journal of Gastroenterology and Hepatology, vol. 19, supplement 7, pp. S150–S154, 2004. View at Publisher · View at Google Scholar
  11. İ. Karagöz and A. Haktanır, “Kronik karaciğer hastalıkları,” Tıp Araştırmaları Dergisi, vol. 2, pp. 33–40, 2004. View at Google Scholar
  12. B. Swolin, S. Safai-Kutti, E. Anghem, and J. Kutti, “No increased frequency of trisomies 8 and 9 by fluorescence in situ hybridization in untreated patients with essential thrombocythemia,” Cancer Genetics and Cytogenetics, vol. 126, no. 1, pp. 56–59, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Bosch, P. Pizcueta, F. Feu, M. Fernandez, and J. C. Garcia-Pagan, “Pathophysiology of portal hypertension,” Gastroenterology Clinics of North America, vol. 21, no. 1, pp. 1–14, 1992. View at Google Scholar · View at Scopus
  14. F. Moriyasu, O. Nishida, N. Ban et al., “‘Congestion index’ of the portal vein,” The American Journal of Roentgenology, vol. 146, no. 4, pp. 735–739, 1986. View at Google Scholar · View at Scopus
  15. A. Wehmeier, I. Daum, H. Jamin, and W. Schneider, “Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients,” Annals of Hematology, vol. 63, no. 2, pp. 101–106, 1991. View at Google Scholar · View at Scopus
  16. I. R. Wanless, P. Peterson, A. Das, J. K. Boitnott, G. W. Moore, and V. Bernier, “Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy,” Hepatology, vol. 12, no. 5, pp. 1166–1174, 1990. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Cervantes, A. Alvarez-Larrán, E. Arellano-Rodrigo, M. Granell, A. Domingo, and E. Montserrat, “Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution,” Leukemia, vol. 20, no. 1, pp. 55–60, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Besses, F. Cervantes, A. Pereira et al., “Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients,” Leukemia, vol. 13, no. 2, pp. 150–154, 1999. View at Google Scholar · View at Scopus
  19. F. Passamonti, E. Rumi, L. Arcaini et al., “Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients,” Haematologica, vol. 93, no. 11, pp. 1645–1651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Sherlock and J. Dooley, Chronic Hepatitis, Disease of the Liver and Biliary System, The Blackwell Science, London, UK, 10th edition, 1997.
  21. U. V. Gentilucci, P. Gallo, G. Perrone et al., “Non-cirrhotic portal hypertension with large regenerative nodules: a diagnostic challenge,” World Journal of Gastroenterology, vol. 17, no. 20, pp. 2580–2584, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. B. K. P. Goh, J. J. C. Chen, H. K. Tan, W. S. Yong, and W. H. Chan, “Acute variceal bleed in a patient with idiopathic myelofibrosis successfully treated with endoscopic variceal band ligation,” Digestive Diseases and Sciences, vol. 52, no. 1, pp. 173–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Abu-Hilal and J. Tawaker, “Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases,” World Journal of Gastroenterology, vol. 15, no. 25, pp. 3128–3133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. S. Nakai, C. G. Craddock, and W. G. Figueroa, “Agnogenic myeloid metaplasia: a survey of twenty-nine cases and a review of the literature,” Annals of Internal Medicine, vol. 57, no. 3, pp. 419–440, 1962. View at Publisher · View at Google Scholar
  25. W. C. Lee, H. C. Lin, S. H. Tsay et al., “Esophageal variceal ligation for esophageal variceal hemorrhage in a patient with portal and primary pulmonary hypertension complicating myelofibrosis,” Digestive Diseases and Sciences, vol. 46, no. 4, pp. 915–919, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. A. E. Dagradi, J. Siemsen, J. Brook, and S. J. Stempien, “Bleeding esophageal varices in myelofibrosis,” The American Journal of Gastroenterology, vol. 44, no. 6, pp. 536–544, 1965. View at Google Scholar · View at Scopus
  27. A. Sullivan, H. Rheinlander, and L. R. Weintraub, “Esophageal varices in agnogenic myeloid metaplasia: disappearance after splenectomy. A case report,” Gastroenterology, vol. 66, no. 3, pp. 429–432, 1974. View at Google Scholar · View at Scopus
  28. D. Roux, J. P. Merlio, A. Quinton, H. Lamouliatte, C. Balabaud, and P. Bioulac-Sage, “Agnogenic myeloid metaplasia, portal hypertension, and sinusoidal abnormalities,” Gastroenterology, vol. 92, no. 4, pp. 1067–1072, 1987. View at Google Scholar · View at Scopus
  29. M. Takasaki, I. Takahashi, M. Takamatsu et al., “Endoscopic injection sclerotherapy for esophageal variceal hemorrhage in a patient with idiopathic myelofibrosis,” Journal of Gastroenterology, vol. 31, no. 2, pp. 260–262, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Bělohlávek, J. Schwarz, A. Jirásek, A. Krajina, F. Polák, and M. Hrubý, “Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS),” Wiener Klinische Wochenschrift, vol. 113, no. 5-6, pp. 208–211, 2001. View at Google Scholar · View at Scopus
  31. N. Tanaka, K. Yamakado, H. Kihira, A. Hashimoto, T. Murayama, and K. Takeda, “Re: transjugular intrahepatic portosystemic shunt for intractable esophageal-gastric variceal hemorrhage in a patient with idiopathic myelofibrosis,” CardioVascular and Interventional Radiology, vol. 23, no. 6, pp. 491–492, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Cortelazzo, G. Finazzi, M. Ruggeri et al., “Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis,” The New England Journal of Medicine, vol. 332, no. 17, pp. 1132–1136, 1995. View at Publisher · View at Google Scholar · View at Scopus